Development and internal validation of a model to predict type 2 diabetic complications after gestational diabetes

Ugochinyere Vivian Ukah1,2, Robert W. Platt1,3,4, Nathalie Auger1,2,5,6, Kaberi Dasgupta1,7 & Natalie Dayan1,7,8

Gestational diabetes mellitus (GDM) increases the risk of early-onset type 2 diabetes, which further exacerbates the risk of developing diabetic complications such as kidney, circulatory, and neurological complications. Yet, existing models have solely focused on the prediction of type 2 diabetes, and not of its complications, which are arguably the most clinically relevant outcomes. Our aim was to develop a prediction model for type 2 diabetic complications in patients with GDM. Using provincial administrative data from Quebec, Canada, we developed a model to predict type 2 diabetic complications within 10 years among 90,143 women with GDM. The model was internally validated and assessed for discrimination, calibration, and risk stratification accuracy. The incidence of diabetic complications was 3.8 (95% confidence interval (CI) 3.4–4.3) per 10,000 person-years. The final prediction model included maternal age, socioeconomic deprivation, substance use disorder, gestational age at delivery, severe maternal morbidity, previous pregnancy complications, and hypertensive disorders of pregnancy. The model had good discrimination (area under the curve (AUROC) 0.72 (95% CI 0.69–0.74)) and calibration (slope ≥ 0.9) to predict diabetic complications. In the highest category of the risk stratification table, the positive likelihood ratio was 8.68 (95% CI 4.14–18.23), thereby showing a moderate ability to identify women at highest risk of developing type 2 diabetic complications. Our model predicts the risk of type 2 diabetic complications with moderate accuracy and, once externally validated, may prove to be a useful tool in the management of women after GDM.

Gestational diabetes mellitus (GDM) is a common metabolic disorder of pregnancy, affecting up to 5–14% of pregnant women1–3. GDM is associated with approximately 20% greater risk of type 2 diabetes in the decade following delivery4,5. Early onset of type 2 diabetes is a risk factor for diabetic complications such as renal disease, circulatory disease, and diabetic acidosis, which pose huge public health concern6,7. Guidelines from national diabetes associations in Canada and the US8,9 recommend screening for type 2 diabetes 6 weeks to 6 months after a pregnancy complicated by GDM. However, this recommendation has been challenging to implement as less than 50% of women with GDM are screened after pregnancy10,11. As the majority of women who have GDM do not develop type 2 diabetes in the short term, targeting high-risk individuals through a risk score may increase screening and interventions to prevent future diabetic complications.

A few models exist to predict the development of type 2 diabetes in women with GDM12,13. These models, however, focus solely on the development of type 2 diabetes, and do not include diabetic complications—arguably the more clinically relevant downstream outcomes accounting for the highest economic burden due to diabetes mellitus6. Furthermore, the small sample sizes of these studies (less than 500 individuals) limit the generalizability of their findings and model application. There are currently no existing models to predict the risk of type 2
Materials and methods

Ethics. The data used for this study were de-identified and ethics review and participant consent were waived by the institutional review board of the University of Montreal Hospital Centre. All methods were carried out in accordance with the Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans.

Study population. We conducted a retrospective cohort study of women who had hospital-based deliveries in Quebec, Canada from April 1989 until March 2016 (cohort entry); women were then followed until 2018 to identify outcomes. The cohort was constructed from the Maintenance and Use of Data for the Study of Hospital Clientele registry, which comprises > 99% of deliveries in Quebec.

Individuals aged 18 to 45 years who had GDM in at least one pregnancy were included, with the cohort entry point (t₀) at the first GDM-affected pregnancy. GDM was defined as abnormal glucose tolerance of the mother, first identified during pregnancy, and identified using diagnostic codes from the 9th and 10th revisions of the International Classification of Diseases (ICD) (Table S1). These codes have been previously validated and adequately capture GDM diagnoses with specificity of > 90% and positive predictive values of > 80% (Table S1).

The secondary outcome was type 2 diabetic complications occurring anytime (up to 29 years) after delivery of the first pregnancy affected by GDM.

Women who died in their first affected pregnancy and women with pre-existing diabetes, or its complications were excluded (Fig. 1).

Outcome. The primary outcome was hospitalization for type 2 diabetic complications within 10 years after delivery of the first pregnancy affected by GDM. Type 2 diabetic complications was defined as a diagnosis of type 2 diabetes with the development of one or more of the following complications: diabetic coma, acidosis, kidney, ophthalmic, neurological, circulatory, or other complications resulting from diabetes and identified using ICD-9 and 10 codes, previously validated in studies with specificity of > 99% and positive predictive values of > 80% (Table S1).

The secondary outcome was type 2 diabetic complications occurring anytime (up to 29 years) after delivery of the first pregnancy affected by GDM.

Women were followed from cohort entry until any of the outcome occurrence, death, or the end of the study period (March 31, 2018).

Statistical analyses. We developed Cox proportional hazards regression models to predict type 2 diabetic complications, according to the previously outlined steps, and report the process using the Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) guidelines (Table S2).

Candidate predictors, variable selection and coding. We considered demographic, reproductive, and clinical factors known to be associated with an increased risk of type 2 diabetes as potential predictor variables. These factors included maternal age, substance use, morbid obesity, socioeconomic deprivation (measured using a composite score of neighbourhood income, education, and employment), pregnancy complications such as parity, and multifetal pregnancy, and pregnancy complications such as hypertensive disorders of pregnancy (HDP), severe maternal morbidity (SMM), stillbirth, preterm delivery, low birthweight, and admission into neonatal intensive care unit (NICU) or adult intensive care unit (ICU). Candidate predictors were measured at the time of the index delivery (cohort entry).

Clinical variables that had low incidence were combined with other similar variables (e.g., previous obstetric complications such as SMM, stillbirth, preterm delivery, low birthweight, NICU admission, or neonatal death were combined). Previous history of obstetric complications was further combined with parity as follows: previous obstetric complication (among multiparous women), no previous obstetric complication (among multiparous women) and no previous obstetric complication (among primiparous women). When collinearity (r > 0.5) existed between variables, the most clinically relevant variable was selected.

Continuous candidate predictor variables (e.g., maternal age) were modelled using restricted cubic splines with three knot locations. We assessed interaction terms and retained predictors that were statistically significant (alpha = 0.10). The final model variables were selected using Least Absolute Selection and Shrinkage Operator (LASSO) regression.

Model performance and internal validation. Predictive performance of the model was assessed based on discriminatory, calibration, and risk stratification accuracy. Discrimination was measured by the c-statistic, which is equivalent to the area under the receiver operating characteristic curve (AUROC). An AUROC of ≥ 0.7 was interpreted as good discrimination and 0.6 to < 0.7 modest, while 0.5 to 0.6 was considered poor and < 0.5 as not having any discriminative ability. Calibration performance was examined by plotting the mean observed
events versus the mean predicted risks by decile. Calibration slopes were interpreted as good (slope > 0.7), poor (0.5 < slope ≤ 0.7) or non-informative (slope ≤ 0.5)24.

Using a risk classification table, we examined the ability of the model to stratify the population into low- and high-risk categories. We divided the population into four risk groups, with the highest calculated risk group corresponding to the overall incidence rate of the outcome in the study population25. Likelihood ratios (LR) were computed to assess the classification accuracy within each group26. For clinical use, positive LRs (LR+) of > 5 or > 10 were interpreted as moderate or good “rule-in” tests, respectively, whereas negative LRs (LR−) of < 0.2 and < 0.1 were considered as moderate or good rule-out tests, respectively24.

The model was assessed for internal validity using the bootstrap method with 200 iterations and the over-optimism (i.e., degree to which a model is overfit) was reported28.

Secondary analyses. Using the same final selected variables, we also developed a prediction model for type 2 diabetic complication up to 29 years after delivery and assessed the model discriminatory performance.
Sample size. We estimated our sample size based on the rule of thumb of 10–20 events per degree of freedom\(^{19}\), to avoid model overfitting. With a total of 1025 events during follow-up, we had sufficient sample size to consider up to 50 degrees of freedom for candidate predictors. Analyses were conducted using R version 3.5.1 (The R Project for Statistical Computing).

Result
Cohort description. Among 1,229,263 women who delivered between 1989 and 2016 in Quebec, our final cohort included 90,143 (7.3%) individuals who met study inclusion criteria (Fig. 1). Among these individuals, the number of people admitted to hospital within 10 years of delivery with any diagnosis of type 2 diabetes, including both complicated and uncomplicated diabetes, was 1858 (2.06%) corresponding to an incidence rate of 25.0 (23.9–26.2) per 10,000 person-years. Within 10 years of delivery, there were 283 (0.3%) women who were hospitalized with type 2 diabetic complications [incidence rate 3.8 per 10,000 person-years (95% CI 3.4–4.3)], (Table 1). The median follow-up time was 6.2 years. The incidence of type 2 diabetic complications was higher for women who were younger than 25 years, obese, had substance use disorders, or were socioeconomically deprived at their first GDM-affected pregnancy, compared with those who did not have these characteristics (Table 1).

| Age, years | Total number of women | Incidence per 10,000 person-years (95% confidence interval) |
|------------|-----------------------|-------------------------------------------------------------|
| <25        | 10,912                | 7.1 (5.5–9.0)                                               |
| 25–29      | 25,703                | 3.7 (3.0–4.6)                                               |
| 30–34      | 30,666                | 3.1 (2.5–3.9)                                               |
| ≥35        | 22,862                | 3.1 (2.3–4.0)                                               |
| Primiparity |                       |                                                             |
| Yes        | 54,342                | 3.9 (3.3–4.5)                                               |
| No         | 35,801                | 3.7 (3.0–4.5)                                               |
| Morbid obesity |                   |                                                             |
| Yes        | 4070                  | 13.6 (9.4–19.1)                                             |
| No         | 86,073                | 3.5 (3.1–3.9)                                               |
| Substance use\(^a\) |                   |                                                             |
| Yes        | 1684                  | 7.2 (3.3–13.6)                                              |
| No         | 88,459                | 3.8 (3.3–4.2)                                               |
| Socioeconomic deprivation |              |                                                             |
| Deprived   | 20,432                | 7.0 (5.8–8.4)                                               |
| Not deprived | 65,308                | 2.8 (2.4–3.3)                                               |
| Time period |                     |                                                             |
| 1989–1995  | 17,250                | 2.0 (1.4–2.7)                                               |
| 1996–2002  | 17,292                | 3.5 (2.7–4.5)                                               |
| 2003–2009  | 23,036                | 5.5 (4.5–6.5)                                               |
| 2010–2016  | 32,565                | 4.1 (3.1–5.2)                                               |
| HDP type   |                       |                                                             |
| No HDP     | 80,858                | 3.3 (2.9–3.8)                                               |
| Pre-existing or unspecified hypertension | 3035 | 6.2 (3.6–9.9)                                               |
| Gestational hypertension | 2864 | 7.5 (4.3–12.2)                                              |
| Pre-eclampsia/HELLP syndrome | 3058 | 9.6 (6.2–14.5)                                              |
| Superimposed pre-eclampsia | 328  | 12.4 (2.6–36.3)                                             |
| Total      | 90,143                | 3.8 (3.4–4.3)                                               |

Table 1. Ten-year incidence of type 2 diabetic complications in women with gestational diabetes mellitus, according to characteristics at cohort entry. \(^a\)Tobacco, alcohol, or drug (cocaine, opioids, stimulants, hallucinogens, sedatives, hypnotics, volatile solvents) use disorders.

Model performance for prediction of type 2 diabetic complications. The final models consisted of seven variables measured at the first GDM-affected pregnancy: maternal age, socioeconomic deprivation, substance use disorder, gestational age at delivery, SMM, previous pregnancy complications, and type of hypertensive disorder of pregnancy (Table 3; prediction model equation is provided in Table S4).
Late diagnosis of type 2 diabetes is often accompanied by development of diabetic complications, which is associated with healthcare expenditures three times greater than treatment of uncomplicated diabetes. Clinically, the ability of type 2 diabetic complications at 10 years is substantial, indicating a robust model.

Over 70% in included studies. Our outcome of interest was hospitalization with type 2 diabetic complications up to 29 years of follow-up was 9.0 (8.5–9.6) per 10,000 person-years, respectively. Possible reasons for the lack of success of previous models include their development in older populations and small sample sizes used in these prior studies and the inclusion of variables not easily measured (e.g. genetic factors) lower the generalizability to routine clinical settings.

Despite advances in our understanding of the association between pregnancy complications and long-term conditions, incorporation of pregnancy factors into existing risk scores has not improved net reclassification. Possible reasons for the lack of success of previous models include their development in older populations and short length of follow-up, making them less suitable for women of reproductive age. Developing prediction models among specific subpopulations, including postpartum women who have had a pregnancy complication, may circumvent some of these issues. Despite the young age of individuals in our cohort, the predicted probability of type 2 diabetic complications at 10 years is substantial, indicating a robust model.

Secondary analyses (prediction of outcome up to 29 years after delivery). The incidence of the type 2 diabetic complications up to 29 years of follow-up was 9.0 (8.5–9.6) per 10,000 person-years, respectively (Table S3). Discriminatory performance decreased slightly, with AUROC of 0.63 (0.61–0.64).

**Discussion**

In this study comprising 90,143 women with GDM, we developed Cox-proportional hazard models to predict the risk of developing type 2 diabetic complications occurring within 10 years of obstetric delivery. The incidence of hospitalization for diabetic complications in this timeframe was low, reflecting the young age of the cohort, and possibly good clinical care. However, our developed models consisting of readily measured variables at the time of birth showed moderate discriminative and calibration abilities for the prediction of type 2 diabetic complications after GDM pregnancy. Although external validation of the model is required, the AUROC of > 0.7 and LR+ of 8.68 in the highest risk category of ≥ 0.03 suggests that the model may eventually be used to reliably identify women at high risk of developing complicated diabetes.

Previous work has established a strong etiologic link between GDM and a future diagnosis of type 2 diabetes mellitus. In a systematic review of 28 studies evaluating the risk of type 2 diabetes risk after GDM, the cumulative incidence of type 2 diabetes varied depending on time since delivery and ethnicity, and ranged from 2.6% to over 70% in included studies. Our outcome of interest was hospitalization with type 2 diabetic complications within 10 years of delivery, reflecting more serious outcomes related to diabetes. The systematic review by Kim et al. also revealed that the cumulative incidence of type 2 diabetes increased over the first 5 years after delivery and plateaued after 10 years, supporting the chosen timeframe for our model.

Previous models have focused on predicting type 2 diabetes after GDM, irrespective of the presence of diabetic complications. A genetic risk score developed by Kwak et al. using data from 395 women with GDM reported a C statistic of 0.775 for predicting type 2 diabetes. Another clinical model which included three types of lipid was developed by Lappas et al. in a cohort of 104 women and had C statistic ranging from 0.756–0.865. These models did not include diabetic complications, which arguably have a more significant impact on women's health, and would justify enhanced surveillance and early aggressive risk reduction therapy. Additionally, the small sample sizes used in these prior studies and the inclusion of variables not easily measured (e.g. genetic factors) lower the generalizability to routine clinical settings.

Despite advances in our understanding of the association between pregnancy complications and long-term conditions, incorporation of pregnancy factors into existing risk scores has not improved net reclassification. Possible reasons for the lack of success of previous models include their development in older populations and short length of follow-up, making them less suitable for women of reproductive age. Developing prediction models among specific subpopulations, including postpartum women who have had a pregnancy complication, may circumvent some of these issues. Despite the young age of individuals in our cohort, the predicted probability of type 2 diabetic complications at 10 years is substantial, indicating a robust model.

**Table 2.** Incidence rates of hospitalization for type 2 diabetic complications among women with gestational diabetes mellitus, within 10 years of delivery, Quebec, 1989 to 2018. N = 90,143. *Foot ulcer, multiple complications, and unspecified complications.

| Total number of women | Incidence per 10,000 person-years (95% confidence interval) |
|-----------------------|-------------------------------------------------------------|
| Diabetes with any complication | 283 | 3.8 (3.4–4.3) |
| Coma | 21 | 0.3 (0.2–0.4) |
| Acidosis | 69 | 0.9 (0.7–1.2) |
| Kidney complications | 63 | 0.8 (0.7–1.1) |
| Ophthalmic | 60 | 0.8 (0.6–1.0) |
| Neurological | 61 | 0.8 (0.6–1.1) |
| Circulatory | 52 | 0.7 (0.5–0.9) |
| Other outcomes* | 200 | 2.7 (2.3–3.1) |

The model had good discriminatory performance for the prediction of type 2 diabetic complications (AUROC 0.72, 95% CI 0.69–0.74) with a mean optimism of 0.0077 upon internal validation, indicating minimal overfitting (Fig. 2). Calibration performance was good with a slope of 0.99 and an intercept of −0.31 (Fig. 3).

In the risk stratification table, the proportion of women with the primary outcome increased in each risk category, as the predicted risk of the outcome increased (Table 4). At the highest risk group (women with calculated risk of ≥ 0.03), 2.5% had the primary outcome whereas only 0.2% in the lowest risk group (women with calculated risk of < 0.006) had the outcome. The resulting LR+ in the highest risk group was 8.68 (95% CI 4.14–18.23) suggesting a moderate rule-in of type 2 diabetic complications in the top 0.3% of the women with the highest calculated predicted risk. However, the confidence interval was wide, due to low number of outcomes in this group (n = 7).

Secondary analyses (prediction of outcome up to 29 years after delivery). The incidence of the type 2 diabetic complications up to 29 years of follow-up was 9.0 (8.5–9.6) per 10,000 person-years, respectively (Table S3). Discriminatory performance decreased slightly, with AUROC of 0.63 (0.61–0.64).
appreciation of risk, logistics of appointments and tests, and concerns of new mothers. A shift in focus on screening strategies based on risk of more severe diabetes may allow for a greater mobilization of resources to a smaller segment of the population with GDM, particularly in lower resource settings. Our study shows that future type 2 diabetic complications can be predicted with moderate accuracy in women with GDM, using readily available clinical variables present in administrative datasets. The advantages of administrative data are that they are population-based records, and are larger than data from clinical settings, therefore our model can forecast future complications for health planning purposes. The model requires external validation before ultimately being converted to an online risk calculator to aid in counselling and triaging of resources in postpartum women with GDM. If the postpartum patient has a calculated high risk, the approach and follow-up would differ (e.g., endocrinology referral, early OGTT, intensive lifestyle approach) from that of a lower-risk patient (e.g., glycosylated hemoglobin, community follow-up, usual postpartum lifestyle recommendations).

Table 3. Final prediction model with coefficients for prediction of type 2 diabetic complications among women with gestational diabetes mellitus, at 10 years of follow-up. Splines are fit for numerical variables and so coefficients are not provided in table. Severe maternal morbidity included conditions defined by the Canadian Perinatal Surveillance System.

| Variables                                      | Model coefficients |
|------------------------------------------------|--------------------|
| **Maternal age**                               |                    |
| Knot 1                                          | Reference          |
| Knot 2                                          | −0.0964            |
| Knot 3                                          | 0.0805             |
| **Socioeconomically deprived**                  |                    |
| No                                              | Reference          |
| Yes                                             | 0.7941             |
| **Substance use**                              |                    |
| No                                              | Reference          |
| Yes                                             | 0.4916             |
| **Gestational age at delivery**                 |                    |
| Knot 1                                          | Reference          |
| Knot 2                                          | 0.0521             |
| Knot 3                                          | −0.3401            |
| **Severe maternal morbidity**                   |                    |
| No                                              | Reference          |
| Yes                                             | 2.7722             |
| **Previous complications**                      |                    |
| No, multiparous                                 | Reference          |
| Yes, multiparous                                | 0.2469             |
| Primiparous                                     | 0.0447             |
| **Hypertensive disorders of pregnancy**         |                    |
| No HDP                                          | Reference          |
| Pre-existing or unspecified hypertension         | −1.610             |
| Gestational hypertension                        | −0.010             |
| Pre-eclampsia/HELLP syndrome                    | 1.690              |
| Superimposed pre-eclampsia                      | −9.7517            |
| **Maternal age**                                |                    |
| Knot 1 severe maternal morbidity (no)           | Reference          |
| Knot 2 severe maternal morbidity (yes)          | 0.1121             |
| Knot 3 severe maternal morbidity (yes)          | 0.1359             |
| **Maternal age**                                |                    |
| Knot 1 no hypertension                          | Reference          |
| Knot 2 pre-existing or unspecified hypertension | 0.0820             |
| Knot 3 pre-existing or unspecified hypertension | −0.1052            |
| Knot 2 gestational hypertension                 | 0.0329             |
| Knot 3 gestational hypertension                 | −0.0790            |
| Knot 2 pre-eclampsia/HELLP syndrome             | −0.0422            |
| Knot 3 pre-eclampsia/HELLP syndrome             | 0.0639             |
| Knot 2 superimposed pre-eclampsia               | 0.3724             |
| Knot 3 superimposed pre-eclampsia               | −0.2730            |
This individualized approach will help with the study, planning, and implementation of targeted preventive strategies at the population level.

Our study has several strengths. First, we used a large population-based cohort of women from Quebec, which represents more than one-quarter of the Canadian population with a diverse multi-ethnic population. We had sufficient sample size for model development and minimal overfitting as shown with internal validation. Second, our data allowed us to test short-term as well as long-term risks of the outcomes. We chose 10 years for the primary prediction period as this represents the time when up to 20% of individuals develop type 2 diabetes. Furthermore, we followed model development methods recommended by experts, including the use of LASSO for final variable selection, rather than forward and backward selections which are more prone to bias. Finally, we ensured transparency in modelling and reporting by following the TRIPOD statement.

As is the case with many large administrative datasets, a downfall is the reliance on ICD codes to define predictors. In particular, the dataset lacked information on clinical parameters such as blood pressure, body mass index, lipid levels or blood glucose measurements which are commonly used in type 2 diabetes clinical prediction models. These continuous variables could potentially improve model discrimination as they increase heterogeneity between women. Other markers of severity of GDM such as insulin levels are predictive of type 2 diabetes.
but were lacking in our dataset\textsuperscript{2}. In addition, we lacked information on ethnicity and family history, which are known determinants of diabetes and its complications\textsuperscript{3}. Our prediction models, therefore, need to be improved and externally validated before they can be considered for use in a clinical setting. Nonetheless, our study identified easily measurable variables that contribute to the prediction of long-term type 2 diabetic complications after GDM. Our models should therefore be used as a foundation to improve upon risk classification after pregnancy.

Finally, it is important to note that the diagnosis of GDM has evolved over time\textsuperscript{34}. However, in un-shown analyses, restricting our population to deliveries prior to 2010, corresponding with the International Association of Diabetes and Pregnancy Study Groups (IADPSG) diagnostic recommendations publication\textsuperscript{34}, did not change model performance.



**Conclusion**

Type 2 diabetic complications can be moderately predicted by our clinical model developed from administrative health data among individuals with a history of GDM. Future work is needed to improve the model performance and test the validity of the model in other datasets. After validation in external cohorts, women with GDM who are at high risk of developing type 2 diabetic complications can be earlier identified immediately after delivery. This will enable individualized planning and targeted approaches, such as endocrinology referral, early OGTT, and appropriate lifestyle modifications, to prevent future type 2 diabetic complications. Simple models to predict diabetic complications such as ours have the potential to help to develop a rational risk-based approach to screening and surveillance after GDM.



**Data availability**

The data that support the findings of this study are available from Institut de la statistique du Québec but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from Institut de la statistique du Québec upon reasonable request and with permission.

Received: 7 March 2022; Accepted: 2 June 2022

Published online: 20 June 2022

**References**

1. Rice, G. E., Illanes, S. E. & Mitchell, M. D. Gestational diabetes mellitus: A positive predictor of type 2 diabetes? Int. J. Endocrinol. 2012, 1–10. https://doi.org/10.1155/2012/721653 (2012).

2. Kim, C., Newton, K. M. & Knopp, R. H. Gestational diabetes and the incidence of type 2 diabetes: A systematic review. Diabetes Care 25(10), 1862–1868. https://doi.org/10.2337/dc05-0896 (2002).

3. Ferrara, A. Increasing prevalence of gestational diabetes mellitus: A public health perspective. Diabetes Care 30(Supplement 2), S141–S146. https://doi.org/10.2337/dc07-s206 (2007).

4. Bellamy, L., Casas, J. P., Hingorani, A. D. & Williams, D. Type 2 diabetes mellitus after gestational diabetes: A systematic review and meta-analysis. The Lancet. 373(9677), 1773–1779. https://doi.org/10.1016/S0140-6736(09)60731-5 (2009).

5. Li, Z. et al. Incidence rate of type 2 diabetes mellitus after gestational diabetes mellitus: A systematic review and meta-analysis of 170,139 women. J. Diabetes Res. 2020, 1–12. https://doi.org/10.1155/2020/3076463 (2020).

6. Zheng, Y., Ley, S. H. & Hu, F. B. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat. Rev. Endocrinol. 14(2), 88–98. https://doi.org/10.1038/nrendo.2017.151 (2018).

7. Cheema, S. et al. Risk factors for microvascular complications of diabetes in a high-risk middle east population. J. Diabetes Res. 2018, 1–7. https://doi.org/10.1155/2018/9864027 (2018).

8. American Diabetes Association. Gestational diabetes mellitus. Diabetes Care 26(Supplement 1), S103–S105. https://doi.org/10.2337/diacare.26.2007.S103 (2003).

9. Diabetes Canada. Canadian Practice Guidelines Expert Committee. Diabetes Canada 2018 clinical practice guidelines for the prevention and management of diabetes in Canada. Can. J. Diabetes. 42(Suppl 1), S1–S25 (2018).

10. Bennett, W. L. et al. Barriers to and facilitators of postpartum follow-up care in women with recent gestational diabetes mellitus: A qualitative study. J. Womens Health. 20(2), 239–245. https://doi.org/10.1089/jwh.2010.2233 (2011).

11. Canadian Diabetes Association. Clinical practice guidelines for the prevention and management of diabetes in Canada [corrected]. (published erratum appears in CAN J Diabetes 2009 Mar; 33(1):46). Can. J. Diabetes. 2008(32), 4–201 (2008).

12. Kwak, S. H. et al. Prediction of type 2 diabetes in women with a history of gestational diabetes using a genetic risk score. Diabetologia 56(12), 2556–2563. https://doi.org/10.1007/s00125-013-3059-x (2013).

13. Lappas, M. et al. The prediction of type 2 diabetes in women with previous gestational diabetes mellitus using lipidomics. Diabetologia 58(7), 1436–1442. https://doi.org/10.1007/s00125-015-3587-7 (2015).

14. Ukah, U. V., Dayan, N., Auger, N., He, S. & Platt, R. W. Development and internal validation of a model predicting premature cardiovascular disease among women with hypertensive disorders of pregnancy: A population-based study in Quebec, Canada. JAMA. 20(9), 20. https://doi.org/10.1001/jama.2019.017328 (2020).

15. Ginde, A. A., Blanc, P. G., Lieberman, R. M. & Camargo, C. A. Validation of ICD-9-CM coding algorithm for improved identification of hypoglycemia visits. BMC Endocr. Disord. 8(1), 4. https://doi.org/10.1186/1472-6823-8-4 (2008).

16. Yasmeen, S., Romano, P. S., Schembri, M. E., Keyzer, J. M. & Gilbert, W. M. Accuracy of obstetric diagnoses and procedures in hospital discharge data. Am. J. Obstet. Gynecol. 194(4), 992–1001. https://doi.org/10.1016/j.ajog.2005.08.058 (2006).

17. Musa, J., Meltzer, S., Bond, R., Garfield, N. & Dasgupta, K. Trends in National Canadian guideline recommendations for the screening and diagnosis of gestational diabetes mellitus over the years: A scoping review. JERPHE. 18(4), 1454. https://doi.org/10.3390/jerph18041454 (2021).

18. Steyerberg, E. W. Clinical Prediction Models: A Practical Approach to Development, Validation, and Updating. (Springer eBooks, New York, 2009).

19. Harrell, J. & Frank, E. Regression Modeling Strategies: With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis 2nd edn. (Springer, 2015). https://doi.org/10.1007/978-3-319-19425-7.

20. Moons, K. G. M. et al. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): Explanation and elaboration. Ann. Intern. Med. 162(1), W1–73. https://doi.org/10.7326/M14-0698 (2015).

21. Kramer, C. K., Campbell, S. & Retnakaran, R. Gestational diabetes and the risk of cardiovascular disease in women: A systematic review and meta-analysis. Diabetologia 62(6), 905–914. https://doi.org/10.1007/s00125-019-4840-2 (2019).
22. Auger, N. et al. Recurrent pre-eclampsia and subsequent cardiovascular risk. *Heart* **103**(3), 235–243. https://doi.org/10.1136/heartjnl-2016-309671 (2017).
23. Dzakpasu, S. et al. Severe maternal morbidity in Canada: Temporal trends and regional variations, 2003–2016. *J. Obstet. Gynaecol. Can.* **41**(11), 1589-1598.e16. https://doi.org/10.1016/j.jogc.2019.02.014 (2019).
24. Ukah, U. V. et al. Temporal and external validation of the fullPIERS model for the prediction of adverse maternal outcomes in women with pre-eclampsia. *Pregnancy Hypertens.* **15**, 42–50. https://doi.org/10.1016/j.preghy.2018.01.004 (2019).
25. Janes, H., Pepe, M. S. & Gu, W. Assessing the value of risk predictions by using risk stratification tables. *Ann. Intern. Med.* **149**(10), 751–760. https://doi.org/10.7326/0003-4819-149-10-200811180-00009 (2008).
26. Deeks, J. J. & Altman, D. G. Diagnostic tests 4: Likelihood ratios. *BMJ* **329**(7458), 168–169. https://doi.org/10.1136/bmj.329.7458.168 (2004).
27. Markovitz, A. R. et al. Does pregnancy complication history improve cardiovascular disease risk prediction? Findings from the HUNT study in Norway. *Eur. Heart J.* **40**(14), 1113–1120. https://doi.org/10.1093/eurheartj/chy863 (2019).
28. Timpka, S. et al. The value of pregnancy complication history for 10-year cardiovascular disease risk prediction in middle-aged women. *Eur. J. Epidemiol.* **33**(10), 1003 (2018).
29. Stuart, J. J. et al. Hypertensive Disorders of pregnancy and 10-year cardiovascular risk prediction. *J. Am. Coll. Cardiol.* **72**(11), 1252–1263. https://doi.org/10.1016/j.jacc.2018.05.077 (2018).
30. Grandi, S. M., Smith, G. N. & Platt, R. W. The relative contribution of pregnancy complications to cardiovascular risk prediction: Are we getting it wrong? *Circulation* **140**(24), 1965–1967. https://doi.org/10.1161/CIRCULATIONAHA.119.040917 (2019).
31. Ravaut, M. et al. Predicting adverse outcomes due to diabetes complications with machine learning using administrative health data. *NPJ Digit Med.* **4**(1), 24. https://doi.org/10.1038/s41746-021-00394-8 (2021).
32. Bonnett, L. J., Snell, K. I. E., Collins, G. S. & Riley, R. D. Guide to presenting clinical prediction models for use in clinical settings. *BMJ* **2019**, 1737. https://doi.org/10.1136/bmj.l737 (2019).
33. Kappen, T. H. et al. Adaptation of clinical prediction models for application in local settings. *Med. Decis. Making.* **32**(3), E1–E10. https://doi.org/10.1177/0272989X12439755 (2012).
34. International Association of Diabetes and Pregnancy Study Groups Consensus Panel et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. *Diabetes Care* **33**(3), 676–682. https://doi.org/10.2337/dc09-1848 (2010).

Acknowledgements

Drs. Dayan, Ukah, Dasguta, and Auger are supported by the Fonds de Recherche de Québec—Santé.

Author Contributions

All the authors have made a significant contribution to this manuscript as follows: U.V.U. conceptualization, data analyses, and original drafting of manuscript; N.D. conceptualization, interpretation of analyses and revising manuscript and editing for important intellectual content, and supervision; R.W.P.: result interpretation, manuscript review and editing for important intellectual content; N.A.: data curation, manuscript review and editing for important intellectual content, and supervision; R.W.P.: result interpretation, and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. *Diabetes Care* **33**(3), 676–682. https://doi.org/10.2337/dc09-1848 (2010).

Competing interests

RWP has consulted for Amgen, Biogen, Merck, Nant Pharma, Pfizer all outside the submitted work. All other authors declare no conflict of interest.

Additional information

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-022-14215-9.

Correspondence and requests for materials should be addressed to N.D.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022